Pasar al contenido principal

Interacción de la inflamación del sistema nervioso periférico y central en la enfermedad de Alzheimer y el síndrome de Down

PI23/01786

•
Nombre agencia financiadora Instituto de Salud Carlos III
Acrónimo agencia financiadora ISCIII
Programa Programa Estatal para Impulsar la Investigación Científico-Técnica y su Transferencia
Subprograma Subprograma Estatal de Generación de Conocimiento
Convocatoria Proyectos de I+D+i en Salud
Año convocatoria 2023
Plan Estatal 2021-2023 Plan Estatal de Investigación Científica y Técnica y de Innovación
Centro beneficiario IIB-SANT PAU. INSTITUTO DE INVESTIGACION HOSPITAL SANTA CRUZ Y SAN PABLO
Centro realización IIB-SANT PAU. INSTITUTO DE INVESTIGACION HOSPITAL SANTA CRUZ Y SAN PABLO

Resultados relacionados

Resultados totales (Incluyendo duplicados): 3
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publicación Artículo de revisión (ReviewArticle)

Clinical and research application of fluid biomarkers in autosomal dominant Alzheimer's disease and Down syndrome

  • Carmona Iragui, Maria|||0000-0001-6914-2339
  • O'Connor, A.
  • Llibre-Guerra, J.
  • Lao, P.|||0000-0003-2243-3547
  • Ashton, Nicholas J.|||0000-0002-3579-8804
  • Fortea, Juan|||0000-0002-1340-638X
  • Sánchez Valle, Raquel|||0000-0001-7750-896X
Autosomal dominant Alzheimer's disease (ADAD) and Down syndrome (DS) constitute genetic forms of Alzheimer's disease (AD). The study of these forms has been crucial in understanding the biomarker changes and disease progression, notably in advancing our knowledge of the natural history of AD. However, some specific characteristics of biomarkers in genetically determined forms and, most importantly, the near full penetrance and predictability of disease onset lead to a very different context of use for biomarkers in these populations. This article delves into the similarities and differences in biomarker profiles between genetically determined AD and sporadic cases, discussing the implications for research and clinical practice. It also emphasizes the need to account for factors that may affect biomarker reliability differently in genetically determined AD. Enhancing our understanding of the disease will pave the way for more personalized therapeutic approaches for affected individuals.
Dipòsit Digital de Documents de la UAB
Publicación Artículo de revisión (ReviewArticle)

Insights into the use of biomarkers in clinical trials in Alzheimer's disease

  • Pascoal, Tharick|||0000-0001-9057-8014
  • Aguzzoli, C.S.
  • Lussier, F.Z.
  • Crivelli, L.
  • Suemoto, C.K.|||0000-0002-5942-4778
  • Fortea, Juan|||0000-0002-1340-638X
  • Rosa-Neto, P.
  • Zimmer, E.R.
  • Ferreira, P.C.L.
  • Bellaver, B.|||0000-0002-2212-3373
Biomarkers have been instrumental in population selection and disease monitoring in clinical trials of recently FDA-approved drugs targeting amyloid-β to slow the progression of Alzheimer's disease (AD). As new therapeutic strategies and biomarker techniques emerge, the importance of biomarkers in drug development is growing exponentially. In this emerging landscape, biomarkers are expected to serve a wide range of contexts of use in clinical trials focusing on AD and related dementias. The joint FDA-NIH BEST (Biomarkers, EndpointS, and other Tools) framework provides standardised terminology to facilitate communication among stakeholders in this increasingly complex field. This review explores various applications of biomarkers relevant to AD clinical trials, using the BEST resource as a reference. For simplicity, we predominantly provide contextual characterizations of biomarkers use from the perspective of drugs targeting amyloid-β and tau proteins. However, general definitions and concepts can be extrapolated to other targets.
Dipòsit Digital de Documents de la UAB
Publicación Artículo de revisión (ReviewArticle)

The Down Alzheimer Barcelona Neuroimaging Initiative (DABNI) and its contributions to understanding Alzheimer's disease in Down syndrome, A decade of discovery

  • Videla Toro, Laura|||0000-0002-9748-8465
  • Benejam, Bessy|||0000-0002-6789-8615
  • Barroeta, Isabel|||0000-0003-2764-7923
  • Fernández, Susana|||0000-0002-9777-1156
  • Altuna-Azkargorta, Miren|||0000-0001-9709-5314
  • Arranz Martínez, Javier|||0000-0003-0891-1215
  • Rodríguez-Baz, Íñigo|||0000-0003-3039-9115
  • Arriola Infante, José Enrique|||0000-0002-3298-4601
  • Hoyo Soriano, Laura del|||0000-0003-4372-1599
  • Illán-Gala, Ignacio|||0000-0002-5418-2052
  • Estellés, Teresa
  • Vaqué-Alcázar, Lídia|||0000-0002-6776-6559
  • Aranha, Mateus|||0000-0001-9594-292X
  • Morcillo Nieto, Alejandra O.|||0000-0003-2202-3521
  • Valldeneu, Silvia|||0000-0003-3497-886X
  • Sánchez-Saudinós, María Belén|||0000-0003-1795-1833
  • Padilla, Concepción|||0000-0003-4102-6787
  • Valle-Tamayo, Natalia|||0000-0001-9322-3710
  • Sánchez-Aced, Érika|||0000-0001-7280-7493
  • Dols Icardo, Oriol|||0000-0003-2656-8748
  • Sirisi Dolcet, Sonia|||0000-0002-5366-7832
  • Muñoz, Laia|||0000-0003-0578-3094
  • Torres Alcalá, Soraya|||0000-0002-7054-2046
  • Sánchez López, Oriol|||0000-0001-9405-1236
  • Garzón, Diana
  • Ribas, Laia
  • Tondo Colomer, Mireia|||0000-0002-0301-9984
  • Camacho, Valle|||0000-0003-0748-0847
  • Giménez, Sandra|||0000-0001-8031-2319
  • Delaby, Constance|||0000-0002-8606-6814
  • Belbin, Olivia|||0000-0002-6109-6371
  • Montal, Victor|||0000-0002-5714-9282
  • Pegueroles, Jordi|||0000-0002-3554-2446
  • Vilaplana, Eduard|||0000-0002-1809-8435
  • Clarimón, Jordi|||0000-0002-6824-6942
  • González-Ortiz, Sofía|||0000-0003-2578-6671
  • Molina-Porcel, Laura|||0000-0003-4068-8578
  • Aldecoa, Iban|||0000-0001-5774-7453
  • Alcolea, Daniel|||0000-0002-3819-3245
  • Bejanin, Alexandre|||0000-0002-9958-0951
  • Videla, Sebastià
  • Blesa, Rafael|||0000-0003-4026-2884
  • Lleó, Alberto|||0000-0002-2568-5478
  • Carmona Iragui, Maria|||0000-0001-6914-2339
  • Fortea, Juan|||0000-0002-1340-638X
  • Maure Blesa, Lucia|||0000-0001-5643-7971
  • Sanjuan, Aída
  • Zsadanyi, Sara E.|||0000-0002-2033-5989
  • Franquesa-Mullerat, Maria|||0009-0006-1484-7132
  • Carreras, Mireia
  • Lorente, Oriol
  • Bounasr El Bennadi, Shaima El
  • Elbachiri, Sumia
  • Mota, Cecilia
  • Iulita, M. Florencia|||0000-0002-3360-4498
Down syndrome (DS) is a genetic form of Alzheimer's disease (AD) that offers crucial insights into AD pathogenesis. The Down Alzheimer Barcelona Neuroimaging Initiative (DABNI) is a population-based multimodal biomarker cohort studying AD's natural history and clinical trials in DS. DABNI included 1135 participants (mean age 42.82, 46.3% female). At baseline, 673 participants were cognitively stable, 113 had prodromal AD, 239 had AD dementia, and 110 were uncertain due to non-AD conditions. Over 10 years, > 10000 clinical visits were conducted; follow-up showed that progression to symptomatic AD before age 40 was rare, but rates increased after age 50 (> 50% within 5 years). Neuropsychological and biomarker assessments demonstrated excellent diagnostic performance and a predictable sequence of changes, similar to autosomal dominant AD. DABNI participates in AD clinical trials and produced approximately 100 publications. The 10-year DABNI study provided critical insights into DS-associated AD (DSAD) and serves as a key platform for DS clinical trials. Highlights: Down Alzheimer Barcelona Neuroimaging Initiative (DABNI) is a population-based multimodal cohort studying Alzheimer's disease in Down syndrome. Over 10 years, 1135 participants contributed to more than 10000 clinical visits and extensive biomarker studies. DABNI findings have transformed the understanding of Alzheimer's disease in Down syndrome, reinforcing its classification as a genetic form of the disease. The cohort integrates clinical care and research, enhancing early detection and patient management. DABNI supports clinical trials and has produced over 100 publications advancing Down syndrome-related Alzheimer's research.